Treatment of Acute Relapses in Multiple Sclerosis

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 97-105

  Berkovich, Regina ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ACTH; Algorithm; Corticosteroids; Plasmapheresis; Relapse

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN G; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; METHYLPREDNISOLONE; NATALIZUMAB; PREDNISONE;

ACNE; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; BACTERIAL ARTHRITIS; BED REST; BLOOD BRAIN BARRIER; BONE DENSITY; BURSITIS; CATARACT; COLOR VISION; CUSHING SYNDROME; DEPRESSION; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DISABILITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHORIA; EDEMA; EUPHORIA; EXPANDED DISABILITY STATUS SCALE; EYE INFECTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART PALPITATION; HEARTBURN; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOMODULATION; INFECTION; INSOMNIA; IRRITABILITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MANIA; MOOD CHANGE; MOON FACE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; OSTEOPENIA; OSTEOPOROSIS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUBCAPSULAR CATARACT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VISUAL ACUITY; WEIGHT GAIN;

EID: 84873138150     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0160-7     Document Type: Review

References (63)

1. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532.
2. Frohman EM, Shah A, Eggenberger E, et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007; 4: 618-626.
3. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurol Clin 2011; 29: 389-400.
4. Hoch E. Ergebnisse verschiedener Behandlungsversuche der multiplen Sklerose an der neurologischen Abteilung der Medizinische und Nervenklinik der Universitat Wiirzburg wahrend der Jahre 1935/ 1936. Wiirzburg: Inaugural-Dissertation. Leipzig: Schneider and Mischkewitz, Naunhof, 1937.
5. Pette H. Die akut entziindlichen Erkrankungen des Nervensystems. Leipzig: Thieme 1942: 516-517.
6. Schaltenbrand G. Die multiple Sklerose des Menschen. Leipzig: Thieme 1943: 238-246.
7. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; 11: 1120-1122.
8. Fog T. Nord. Med 1951; 46: 1742.
9. Jnsson B, von Reis G, Sahlgren E. Acta Psychiat 1951; 74: 60.
10. Alexander L, Cass LJ. The present status of ACTH therapy in multiple sclerosis. Ann Intern Med 1963: 58: 454-471.
11. Millar JHD, Belf MD, Vas CJ, et al. Long-term treatment of multiple sclerosis with corticotrophin. The Lancet 1967; 7513: 429-431.
12. Rinne UK, Sonninen V, Tuovinen T. Corticotrophin treatment in multiple sclerosis. Acta Neurologica Scandinavica 1967; 31: 185-186.
13. Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbation. Trans Am Neurol Assoc 1969; 94: 126-133.
14. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo - final report. Neurology 1970; 20: 1-59.
15. Questcor Pharmaceuticals, Inc. H. P. Acthar® Gel (repository corticotrophin injection) [prescribing information]. Hayward, CA: Questcor Pharmaceuticals, Inc.; June 2011.
16. Hoogstraten MC, Cats A, Minderhoud JM. Bed rest and ACTH in the treatment of exacerbations in multiple sclerosis patients. Acta Neurol Scand 1987; 76: 346-350.
17. Hoogstraten MC, Minderhoud JM. Long-term effect of ACTH treatment of relapse in multiple sclerosis. Acta Neurol Scand 1990; 82: 74-77.
18. Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6: 267-273.
19. Abbruzzese G, Gandolfo C, Loeb C. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci 1983; 2: 169-172.
20. Barnes M, Bateman D, Cleland P, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48: 157-159.
21. Milanese C, La Mantia L, Salmaggi A, et al. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 1989; 29: 10-14.
22. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-971.
23. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-243.
24. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-516.
25. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 9: 581-588.
26. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-534.
27. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-906.
28. Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73: 1842-1848.
29. Cass LJ, Alexander L, Enders M. Complications of corticotropin therapy in multiple sclerosis. JAMA 1966; 197: 173-178.
30. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-364.
31. Schwid SR, Goodman AD, Puzas JE, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 8: 753-757.
32. Zorzon M, Zivadinov R, Locatelli L, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005; 7: 550-556.
33. Weiner ES, Abeles M. Aseptic necrosis and glucocorticois in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989; 16: 604-608.
34. Fardet L, Kassar A, Cabane J, et al. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007; 30: 861-881.
35. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
36. Feldman-Billard S, Lissak B, Kassaei R, et al. Short-term tolerance of pulse methylprednisolone therapy in patients with diabeles mellitus. Ophthalmology 2005; 112: 511-515.
37. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic horone (ACTH) gel. Drug Des Devel Ther 2011; 5: 147-153.
38. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy. Pediatr Neurol 2005; 33: 121-126.
39. Stafstrom CE, Arnason BG, Baram TZ, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol 2011; 11: 1411-1421.
40. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56: 1-29.
41. Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci 2008; 31: 353-360.
42. Arnason B, Berkovich R, Catania A., et al. Therapeutic mechanisms of action of adrenocorticotropic hormone (ACTH) and other melanocortin peptides for the clinical management of patients with MS. 2012;(in press).
43. Poser CM. Corticotropin is superior to corticosteroids in the treatment of MS. Arch Neurol 1989; 46: 946.
44. Berkovich R, Fernandez M, Subhani D. Adrenocorticotropic hormone treatment of multiple sclerosis exacerbations. Presented at the Consortium of Multiple Sclerosis Centers; June 2, 2012; San Diego.
45. Zaidi M, Sun L, Robinson LJ, et al. ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sci USA 2010; 107: 8782-8787.
46. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
47. Berkovich R, Subhani D, Steinman L. Autoimmune Comorbid Conditions in Multiple Sclerosis. US Neurol 2011; 7: 132-138.
48. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosupression for acute attacks of multiple sclerosis. Neurology 1989; 38: 1143-1149.
49. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
50. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-146.
51. Keegan M, Konig F, Mcclelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582.
52. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-625.
53. Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68: 1614-1617.
54. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
55. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15: 1163-1167.
56. Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebocontrolled pilot study of i. v. immune globulins in combination with i. v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10: 89-91.
57. Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63: 2028-2033.
58. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810.
59. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-2043.
60. Cortese V, Chaudhry YT, So F, et al. Evidence-based guideline update: plasmapheresis in neurologis disorders: report of the therapeutics and technology assessment subcommittee of the Americal Academy of Neurology. Neurology 2011; 76: 294-300.
61. Perumal JS, Caon C, Hreha S, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008; 7: 677-680.
62. Brod SA, Morales MM. Bio-equivalence of intramuscular and subcutaneous H. P. Acthar Gel. Biomed Pharmacother 2009; 63: 251-253.
63. Simsarian JP, Saunders C, Smith DM, Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther 2011; 5: 381-389.